Rampart Appoints Gary Burbach as Chairman of the Board

February 4, 2026—Rampart, an Alabama-based medical device company focused on interventional radiation safety, announced the appointment of Gerhard (Gary) F. Burbach as Chairman of its Board of Directors.

Rampart, which is an Alabama-based developer of barrier-based radiation protection, recently announced the SECURE clinical program, a coordinated series of clinical studies spanning multiple interventional specialties to evaluate the use of Rampart’s suite of enhanced radiation protection devices.

Rampart stated that Burbach was President, Chief Executive Officer, and a member of the Board of Directors of Thoratec Corporation, where he helped pioneer mechanical circulatory support technologies for treatment of advanced heart failure. Thoratec was acquired by St. Jude Medical, now part of Abbott Laboratories.

Currently, Burbach is a member of the Board of Directors and Chair of the Compensation Committee of BWX Technologies; Chairman of the Board of Directors of Procyrion, Inc.; and member of the Board of Directors of Sight Sciences, Inc., noted Rampart.

“Rampart is addressing a long-standing challenge in interventional medicine, providing better care to those who care for us,” commented Burbach in the company’s press release. “The company’s clear value proposition of drastically reducing radiation exposure and helping eliminate the physical burden associated with traditional lead protection position it to fundamentally change radiation safety in the interventional suite. I am excited to work with the Board and leadership team to help Rampart realize its full potential.”

Tom Livingston, Chief Executive Officer of Rampart, added, “We are delighted to welcome Gary as Chairman of the Board at a pivotal moment for Rampart. Gary brings decades of proven leadership across the medical device industry, with deep experience scaling transformative technologies, building market-leading companies, and establishing new standards of care. His track record of commercial execution, operational excellence, and strategic governance will be invaluable as Rampart continues to expand adoption of its interventional radiation safety platform and advance our mission to protect clinicians without compromise.”